{"prompt": "['MC1752', '46', 'System Organ Class', 'CTCAE Grade at which the event', '(SOC)', 'Adverse event/ Symptoms', 'will not be expeditedly reported', 'General disorders and', 'Fatigue', 'Grade 3', 'administration site', 'Malaise', 'Grade 3', 'conditions', 'Skin and subcutaneous', 'Rash', '<Grade 4', 'tissue disorders', 'Erythema', '<Grade3', 'Colitis', '<Grade 3', 'Gastrointestinal disorders', 'Nausea', '<Grade 3', 'Vomiting', '<Grade 3', 'Renal and urinary', 'Cystitis', 'Grade3', 'disorders', 'Injury, poisoning and', 'Radiation dermatitis', '<Grade 3', 'procedural complications', 'Blood and lymphatic', 'Anemia', '<Grade 4', 'system disorder', 'Respiratory, thoracic and', 'Pneumonitis', '<Grade 3', 'mediastinal disorders', '1', 'These exceptions only apply if the adverse event does not result in hospitalization. If the adverse event', 'results in hospitalization, then the standard expedited adverse events reporting requirements must be', 'followed.', 'Specific protocol exceptions to expedited reporting should be reported expeditiously by investigators', 'ONLY if they exceed the expected grade of the event.', 'The following hospitalizations are not considered to be SAEs because there is no \"adverse event\" (i.e.,', 'there is no untoward medical occurrence) associated with the hospitalization:', 'Hospitalizations for respite care', 'Planned hospitalizations required by the protocol', 'Hospitalization planned before informed consent (where the condition requiring the hospitalization has', 'not changed post study drug administration)', 'Hospitalization for elective procedures unrelated to the current disease and/or treatment on this trial', 'Hospitalization for administration of study drug or insertion of access for administration of study drug', 'Hospitalization for routine maintenance of a device (e.g., battery replacement) that was in place before', 'study entry', 'Hospitalization, or other serious outcomes for signs and symptoms of progression of the cancer.', '10.4', 'Expedited Reporting Requirements for IND/IDE Agents', '10.41', 'Phase 1 and Early Phase 2 Studies: Expedited Reporting Requirements for Adverse', 'Events that Occur on Studies under an IND/IDE within 30 Days of the Last', 'Administration of the Investigational Agent/Intervention 1,2', 'Protocol Version Date: 21JUN2018']['MC1752', '47', 'FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)', 'NOTE: Investigators MUST immediately report to the sponsor ANY Serious Adverse Events, whether or not they are', 'considered related to the investigational agent(s)/intervention (21 CFR 312.64)', 'An adverse event is considered serious if it results in ANY of the following outcomes:', '1) Death', '2)', 'A life-threatening adverse event', '3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization for 24 hours', '4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions', '5)', 'A congenital anomaly/birth defect.', '6)', 'Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be', 'considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require', 'medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A', 'and ICH E6).', 'ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the sponsor within the', 'timeframes detailed in the table below.', 'Grade 3-5', 'Hospitalization', 'Grade 1 and Grade 2 Timeframes', 'Timeframes', 'Resulting in', 'Hospitalization', '7 Calendar Days', '>24 hrs', '24-Hour 3 Calendar Days', 'Not resulting in', 'Hospitalization', 'Not required', '>24 hrs', 'Expedited AE reporting timelines are defined as:', '\"24-Hour; 3 Calendar Days\" - The AE must initially be reported within 24 hours of learning of the AE, followed by a', 'complete expedited report within 3 calendar days of the initial 24-hour report.', '\"7 Calendar Days\" - A complete expedited report on the AE must be submitted within 7 calendar days of learning of', 'the AE.', '1-Serious adverse events that occur more than 30 days after the last administration of investigational agent/intervention', 'and have an attribution of possible, probable, or definite require reporting as follows:', 'Expedited 24-hour notification followed by complete report within 3 calendar days for:', 'All Grade 3, 4, and Grade 5 AEs', 'Expedited 7 calendar day reports for:', 'Grade 2 AEs resulting in hospitalization or prolongation of hospitalization', '2', 'For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive half-lives, rounded UP', 'to the nearest whole day, after the agent/intervention was last administered. Footnote \"1\" above applies after this', 'reporting period.', 'Effective Date: May 5, 2011', 'NOTE: Refer to Section 10.32 for exceptions to Expedited Reporting', '10.42 General reporting instructions', 'The Mayo IND Coordinator will assist the sponsor-investigator in the processing of expedited', 'adverse events and forwarding of suspected unexpected serious adverse reactions (SUSARS) to', 'the FDA and IRB.', 'Use Mayo Expedited Event Report', 'form', 'for investigational agents or commercial/investigational agents on the same', 'arm.', 'See section 10,8 for submission requirements to EMD Serono.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}